Navigate
ims logo
print

IMS PharmaDeals Review of 2015: Return of the mega-merger and a shift to early-stage dealmaking

In an era of low sales growth, pharmaceutical companies have looked to M&A in attempt to maintain profit growth, and in 2015, we saw the return of the mega-merger. Additionally, key companies such as AstraZeneca and Pfizer took the lead in dealmaking and deal spend. The highest upfront payments for licensing deals were reserved for clinical stage assets in immuno-oncology, inflammatory disease and diabetes therapy areas, and with more than 30% of deals signed in 2015, oncology continued to dominate the dealmaking landscape. In this white paper, IMS PharmaDeals analyses the deal trends of 2015 for you. 

Download the White Paper

Please complete the form below to request our IMS PharmaDeals Review of 2015 white paper:

 

Required*